Introduction {#Sec1}
============

Human immunodeficiency virus (HIV) infects CD4+ cells, where a viral envelope glycoprotein gp120 interacts with a receptor CD4 and a co-receptor CXCR4 or CCR5 of the host cells, and subsequent insertion of a viral envelope glycoprotein gp41 into the host cell membrane triggers the fusion followed by entry of the virus (Kilby and Eron [@CR35]). gp120 is a highly glycosylated protein, as half of its total mass is accounted by about 24 N-linked glycans including complex and high-mannose types (Geyer et al. [@CR20]). These densely attached *N*-glycans shield the viral surface proteins to escape from neutralizing antibody recognition (Wei et al. [@CR60]; Bonomelli et al. [@CR8]). On the other hand, carbohydrate-binding agents that target those glycans on the viral envelope exhibit potent antiviral activities via interfering the interaction between gp120 and CD4 (Hansen et al. [@CR22]; Balzarini et al. [@CR3]; Charan et al. [@CR10]; Dey et al. [@CR15]; Swanson et al. [@CR57]).

Several high-mannose *N*-glycan-binding lectins are newly found and marked as potential microbicides having anti-HIV activities, such as cyanobacterial lectins of cyanovirin-N (CV-N) from *Nostoc ellipsosoprum* (Boyd et al. [@CR9]), scytovirin (SVN) from *Scytonema varium* (Bokesch et al. [@CR7]), and *Microcystis viridis* lectin (MVL) from *Mycrosystis viridis* (Bewley et al. [@CR5]), a bacterial lectin of actinohivin (AH) from actinomycete *Longispora albida* (Chiba et al. [@CR12]), and algal lectins of griffithsin (GRFT) from a red alga *Griffithsia* sp. (Mori et al. [@CR42]), and *Boodlea coacta* agglutinin (BCA) from a green alga *Boodlea coacta* (Sato et al. [@CR53]). These lectins show strong anti-HIV activities through their binding to mannoside structures on gp120. However, high-mannose recognition mode subtly differed among them, as well as the primary structure were clearly distinct (Sato et al. [@CR53]; Koharudin and Gronenborn [@CR37]). High-mannose *N*-glycan structures are also present on the surfaces of the other enveloped viruses such as influenza virus, hepatitis C virus (HCV), human herpes virus (HHV), West Nile virus, severe acute respiratory syndrome-related coronavirus (SARS-CoV), and Ebola virus (Okuno et al. [@CR46]; Vigerust and Shepherd [@CR59]). This suggests that high-mannose binding lectins could also inactivate the entries of those viruses into host cells (Barrientos et al. [@CR4]; Helle et al. [@CR23]; O'Keefe et al. [@CR44], [@CR45]).

A lectin ESA-2 from a red alga *Eucheuma serra* (Kawakubo et al. [@CR33]) was recently found to possess the unique binding specificity with the preferential affinity for high-mannose *N*-glycans bearing the nonreducing terminal α1-3 Man in D2 arm (Hori et al. [@CR26]). Since then, several lectins with similar binding specificity were isolated from some lower organisms, including red algae (Kawakubo et al. [@CR34]; Sato et al. [@CR52]; Hung et al. [@CR28], [@CR29]), a cyanobacterium (Sato et al. [@CR50], [@CR51]), and bacteria (Cumsky and Zusman [@CR13]; Sato et al. [@CR54]; Koharudin et al. [@CR39]; Whitley et al. [@CR61]). Interestingly, these lectins commonly had tandem-repeated structures of a similar domain composed of about 67 amino acids and grouped into two types of four and two repeats (Hori et al. [@CR26]; Sato et al. [@CR51]; Sato and Hori [@CR49]), as exemplified with ESA-2 (four repeats) and a lectin OAA (two repeats) from a freshwater cyanobacterium *Oscillatoria agardhii*. Thus, we demonstrated the occurrence of a new lectin family which is widely distributed in lower organisms, indicating that ESA-2 and OAA are orthologous to each other. Among them, OAA has been characterized in details. The structural analyses of OAA and its complexes with oligomannosides revealed that this lectin recognized a core unit, Manα1-6(Manα1-3)Manα1-6(Manα1-3)Manβ- of the branched mannoside in high-mannose *N*-glycan (Koharudin et al. [@CR38]; Koharudin and Gronenborn [@CR36], [@CR37]). This recognition mode of OAA was novel as the other high-mannose binding lectins mostly recognized the nonreducing end mannoses. Potent anti-HIV activities of this lectin family, including ESA-2, OAA, *Pseudomonas fluorescens* agglutinin (PFA), *Myxococcus xanthus* agglutinin (myxobacterial hemagglutinin, MBHA) (Koharudin et al. [@CR39]), and *Burkholderia oklahomensis* agglutinin (BOA) (Whitley et al. [@CR61]) were represented as expected by their specific binding nature to high-mannose sugar moiety. Strong anti-influenza virus activities through binding to the envelope hemagglutinin protein were also shown in PFL (identical to PFA) (Sato et al. [@CR54]), and KAA-2 isolated from a cultivated red alga *Kappaphycus alvarezii* (Sato et al. [@CR52]).

Algae belonging to genus *Eucheuma* and *Kappaphycus* are widely cultivated as food and carageenophyte. *K. alvarezii* cultivation was originally started in the Philippines in latter half of the 1960s using the local varieties selected from the wild (Doty [@CR17]; Parker [@CR48]; Bindu and Levine [@CR6]). After four decades, the *Kappaphycus* became the most widely cultivated commercial eucheumoid (Bindu and Levine [@CR6]) and has globally been introduced for cultivation and some experimental purposes in tropical and subtropical area, including Asia, Africa, the Pacific Island, and American countries (Ask et al. [@CR2]; Bindu and Levine [@CR6]). We recently reported that KAA-2 isolated from the cultivated sample of *K. alvarezii* preferentially recognized high-mannose-type oligosaccharides bearing an exposed α1-3 Man at the nonreducing end in D2 arm and inhibited infection of various influenza virus strains with EC~50~s of low nanomolar levels through direct binding to the viral envelope hemagglutinin protein, which has several high-mannose *N*-glycans (Sato et al. [@CR52]). The results also suggest that KAA-2 may belong to a new lectin family mentioned above. However, the primary structure of KAA is unknown yet as well as its anti-HIV activity.

In this study, we elucidated the primary structure of KAA-2 using peptide mapping and complementary DNA (cDNA) cloning and prepared its active recombinants using an *Escherichia coli* expression system. The native and recombinant lectins were examined for sugar binding specificity and anti-HIV activity, including binding nature to gp120.

Materials and Methods {#Sec2}
=====================

Materials {#Sec3}
---------

*K. alvarezii* lectins KAA-1 and KAA-2 (previously declared as ECA-1 and ECA-2) and *Eucheuma serra* lectin ESA-2 were prepared as described previously (Kawakubo et al. [@CR33], [@CR34]) and kept at −20 °C until use. The cultivated specimen of *K. alvarezii* was stored in RNAlater (Life Technologies, CA, USA) at −20 °C until RNA extraction. A vector pGEM-T Easy (Promega, WI, USA) and *E. coli* strain DH-5α were used for subcloning PCR amplified products. An expression vector pET-28a(+) (Merck, Darmstadt, Germany) and an *E. coli* strain SHuffle T7 Express (New England Biolabs, MA, USA) were used for recombinant lectin preparation. Pyridylaminated (PA)-sugars were purchased from Takara Bio (Tokyo, Japan), except PA-derivatives of oligomannosides including mannotriose (Manα1-6(Manα1-3)Man-OH) and mannopentaose (Manα1-6(Manα1-3)Manα1-6(Manα1-3)Man-OH) which were previously prepared (Hori et al. [@CR26]). A recombinant glycosylated HIV-1 IIIB gp120 (baculovirus) was purchased from ImmunoDiagnostics (MA, USA). Jurkat cells and T lymphocyte-derived cells were propagated in RPMI 1640 medium (Life Technologies) supplemented with 10 % fetal calf serum (Nichirei Biosciences, Tokyo, Japan).

Preparation of *S*-Pyridylethylated Lectins {#Sec4}
-------------------------------------------

KAA-2 and ESA-2 were subjected to *S*-pyridylethylation according to the method described previously (Hori et al. [@CR26]). *S*-pyridylethylated (PE-) KAA-2 and PE-ESA-2 were purified by reverse-phase (RP-) HPLC on YMC-Pack PROTEIN-RP (6.0 × 250 mm, YMC, Kyoto, Japan). Briefly, after injection of sample to the column equilibrated with 10 % (*v*/*v*) acetonitrile in 0.05 % (*v*/*v*) trifluoroacetic acid (TFA), the column was washed with the same solvent for 10 min and then eluted with a linear gradient (10--70 %) of acetonitrile in 0.05 % TFA for 30 min at a flow rate of 1.0 ml/min. The eluate was monitored by absorbance at 280 nm (A280), and the active fractions were recovered. SDS-PAGE for purified proteins was performed using a 15 % (*w*/*v*) gel (Schägger and von Jagow [@CR55]).

Trypsin Digestion and Separation of Peptides {#Sec5}
--------------------------------------------

One hundred micrograms each of PE-KAA-2 and PE-ESA-2 was digested with [l]{.smallcaps}-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin (Roche Diagnostics, Basel, Switzerland) (enzyme/substrate = 1:50 (*w*/*w*)) in 1 % (*w*/*v*) ammonium hydrogen carbonate at 37 °C for 24 h. For the isolation of peptide fragments, each digest was separated by RP-HPLC on TSKgel ODS-120T column (4.6 × 250 mm, Tosoh, Tokyo, Japan). Briefly, the digest was applied to the column equilibrated with 5 % (*v*/*v*) acetonitrile in 0.1 % (*v*/*v*) TFA. The column was washed with the same solvent for 5 min and then eluted with a linear gradient (5--65 %) of acetonitrile in 0.1 % TFA for 60 min at a flow rate of 1.0 ml/min. The eluate was monitored by absorbance at 220 nm (A220), and the active fractions were recovered.

Molecular Weight Determination {#Sec6}
------------------------------

The molecular masses of purified PE-KAA-2, PE-ESA-2, and their trypsin-digested peptides were determined by electron spray ionization (ESI)-mass spectrometry (MS) using Finnigan LCQ (Thermo Fisher Scientific, MA, USA). The masses of purified recombinants were determined by ESI-MS using LTQ Orbitrap XL (Thermo Fisher Scientific).

N-Terminal Amino Acid Sequencing {#Sec7}
--------------------------------

The N-terminal amino acid sequences of PE-KAA-2 and the peptide fragments produced by trypsin digestion of PE-KAA-2 were determined by a protein sequencer Procise 492 HT (Life Technologies).

cDNA Cloning of KAAs {#Sec8}
--------------------

Total RNA was extracted from 2.5 g of the RNAlater-treated alga of *K. alvarezii* using 25 ml of a Plant RNA Isolation Reagent (Life Technologies). Messenger RNA (mRNA) purification from the total RNA was performed using a NucleoTrap mRNA Purification Kit (Macherey-Nagel, Düren, Germany). Full-length cDNAs were synthesized from 50 ng of a mRNA using GeneRacer Kit (Life Technologies) according to the manufacturer's instruction. The first PCR for rapid amplification of the cDNA 5′end (5′RACE) was performed with a 50-μl reaction mixture containing 5 μl of 10 × Blend Taq buffer (Toyobo, Osaka, Japan), 10 nmol each of dNTP, 30 pmol of GeneRacer 5′ Primer (Life Technologies) (5′-CGACTGGAGCACGAGGACACTGA-3′), 250 pmol of a degenerated primer KAA_5′RACE_R1 (5′-ATIGGICCYTCICCYTTRTAYTGC-3′), which was designed from the partial amino acid sequence of KAA-2 predicted by peptide mapping, 1 μl of tenfold diluted synthesized cDNA, and 1.25 U of Blend Taq DNA polymerase (Toyobo). Thermal cycling conditions consisted of denaturation at 94 °C for 3 min, followed by 30 cycles consisting of denaturation at 94 °C for 30 s, annealing at 64 °C for 30 s, and extension at 72 °C for 1 min, and the final extension step at 72 °C for 5 min. The nested PCR was performed by the same method, except that 1 μl of a 100-fold diluted solution containing the first PCR product was used as a template, 10 pmol of GeneRacer 5′ Nested Primer (5′-GGACACTGACATGGACTGAAGGAGTA-3′) and 250 pmol of a degenerated primer KAA_5′RACE_R2 (5′-AYTGRTTYTCIACRTTRTAIGTRTC-3′) as a primer pair and that the annealing of the reaction was performed at 58 °C. Nested PCR products were subcloned into pGEM-T Easy vector (Promega). DNA sequencing was performed using BigDye Terminator Cycle Sequencing Kit Ver. 3.1 with ABI 3130xl DNA sequencer (Life Technologies).

3′RACE was performed by the same method of 5′RACE as described above, except that a primer pair of GeneRacer 3′ Primer (5′-GCTGTCAACGATACGCTACGTAACG-3′) and a degenerated primer KAA_3′RACE_F1 (5′-AYACITAYAAYGTIGARAAYCARTGGGG-3′) for the first PCR and GeneRacer 3′ Nested Primer (5′-CGCTACGTAACGGCATGACAGTG-3′) and a degenerated primer KAA_3′RACE_F2 (5′-ARTAYAARGGIGARGGICCIATHGG-3′) for the nested PCR were used. At last, the full-length cDNAs encoding two KAA isolectins were amplified using a high-fidelity DNA polymerase KOD FX Neo (Toyobo) with primer pairs of KAA1_5′End_F (5′-TATAGCTGAGTCAAGTTACACCAAC-3′) and KAA1_3′End_R (5′-AGAGGGTGATCACGTTTTTAC-3′) or KAA2_5′End_F (5′-ACCACCAGCACCGTGCTACTCGCT-3′) and KAA2_3′End_R (5′-GAATGTCCTTACGTGGCCTTTAC-3′), which were designed from the 5′ and 3′ terminal sequences of KAA cDNAs obtained by 5′ and 3′RACEs.

Sequence Data Processing {#Sec9}
------------------------

Homologous sequences were searched with the basic local alignment search tool (BLAST) program. Amino acid sequence comparison with homologous proteins from various organisms was performed using Clustal Omega (Sievers et al. [@CR56]).

Construction of Expression Vector for Recombinant KAA-1 {#Sec10}
-------------------------------------------------------

The recombinant KAA-1 gene was designed by back-translation from its amino acid sequence and synthesized by Integrated DNA Technologies (IA, USA). The KAA-1 coding region flanked by the restriction enzyme recognition sites was amplified by means of the PCR using a primer pair of rKAA1_F (5′-GATA[GCTAGC]{.ul}GGCCGCTATACAGTTCAAAACC-3′) and rKAA1_R (5′-GATC[CTCGAG]{.ul}TTAGCTCGCCACGCCTTTAAAG-3′), where underlined nucleotides represent the recognition sites for *Nhe* I and *Xho* I, respectively. The PCR using PrimeSTAR HS DNA Polymerase (Takara Bio) consisted of denaturation at 98 °C for 5 min, followed by 30 cycles consisting of denaturation at 98 °C for 10 s, annealing at 60 °C for 5 s, and extension at 72 °C for 70 s, and the final extension step at 72 °C for 5 min. An amplified DNA fragment was subcloned into pET-28a(+) (Merck) to yield pET28a-rKAA1, which can express recombinant KAA-1 (rKAA-1) with the N-terminal hexa-His-tag followed by the thrombin cleavage site (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1A diagram of recombinant KAA-1 (rKAA-1) expression vector pET28a-rKAA1. rKAA-1 was expressed as a 6-His- and thrombin cleavage site-fused protein

Expression of Recombinant KAA-1 {#Sec11}
-------------------------------

*E. coli* SHuffle T7 Express strain (New England Biolabs), which is an enhanced BL21 derivative engineered to express a chromosomal copy of the disulfide bond isomerase DsbC (Chen et al. [@CR11]) in the cytoplasm constitutively, was transformed with the rKAA-1 expression vector pET28a-rKAA1 by a conventional method. A transformant was cultured with 1 L of LB media at 37 °C until OD~600~ reached 0.5, and then IPTG was added at a final concentration of 0.1 mM. After continuously cultured at 20 °C for 16 h, the bacteria cells were harvested by centrifugation at 10,000 g for 20 min. After fracturing the cell by sonication, the His-tagged rKAA-1 (His-rKAA-1) expressed into soluble fraction was purified by His GraviTrap (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's instruction. After purification, His-rKAA-1 was dialyzed thoroughly against ultrapure water to remove imidazole which was contained in the elution buffer. Twenty-five milligrams of His-rKAA-1 was then applied to thrombin treatment using a Thrombin Cleavage Capture Kit (Merck) to disconnect the tag peptide from the recombinant according to the manufacturer's instruction. After removal of thrombin by the above kit, the digested fraction was applied to His GraviTrap to exclude the cleaved His-tag peptide and undigested His-rKAA-1. Generated rKAA-1 was then dialyzed thoroughly against ultrapure water.

Measurement of Protein Concentrations {#Sec12}
-------------------------------------

The A280 of solution was measured with NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). Crude protein concentrations were represented as A280 at 1.0 mg/ml is 1.0. The purified protein concentrations were determined by calculating from A280 and their extinction coefficients which are computed from amino acid sequences (Gill and von Hippel [@CR21]; Pace et al. [@CR47]).

Hemagglutination Assay and Hemagglutination-Inhibition Test {#Sec13}
-----------------------------------------------------------

Hemagglutination assay was performed using a 2 % (*v*/*v*) suspension of trypsin-treated rabbit erythrocytes (TRBCs) as described previously (Hori et al. [@CR25]). Hemagglutination activity was expressed as a titer, the reciprocal of the highest twofold dilution exhibiting positive hemagglutination. Hemagglutination-inhibition assay was also performed using a 2 % (*v*/*v*) suspension of TRBC and following sugars and glycoproteins as described in Hori et al. ([@CR25]); [d]{.smallcaps}-glucose, [d]{.smallcaps}-galactose, [d]{.smallcaps}-mannose, [d]{.smallcaps}-xylose, *N*-acetylglucosamine, *N*-acetylgalactosamine, *N*-acetylneuraminic acid, [l]{.smallcaps}-fucose, [l]{.smallcaps}-rhamnose, lactose, transferrin (human), asialo-transferrin, fetuin (type III, fetal calf serum), asialo-fetuin, yeast mannan, porcine thyroglobulin (PTG), asialo-PTG, bovine submaxillary mucin (BSM), and asialo-BSM. The inhibitory activity was expressed as the minimum concentration of sugar (mM) or glycoprotein (μg/ml) that completely inhibited the activity of a lectin solution of hemagglutination titer 8.

Centrifugal Ultrafiltration-HPLC Method for Determining Oligosaccharide Binding Specificity of rKAAs {#Sec14}
----------------------------------------------------------------------------------------------------

The oligosaccharide binding activity of rKAAs was determined by a centrifugal ultrafiltration HPLC method as described in Hori and Hirayama ([@CR24]). Briefly, 90 μl of 500 nM His-rKAA-1 or rKAA-1 in 50 mM Tris--HCl (pH7.0) and 10 μl of 300 nM PA-oligosaccharide were mixed and kept at room temperature for 60 min. Subsequently, unbound PA-oligosaccharides were collected by centrifugation (10,000*g*, 30 s) using Nonosep 10K Device (Pall, NY, USA). An aliquot of the filtrate was applied to a TSKgel ODS 80TM column (4.6 × 150 mm, Tosoh) and unbound PA-oligosaccharide was quantified from the peak area. The amount of bound PA-oligosaccharide was obtained by subtracting the amount of unbound oligosaccharide from the amount of added oligosaccharide, which was determined from the filtrate of the reaction solution without a lectin. The binding activity (%) was calculated as the ratio of the amount of bound oligosaccharide to that of added oligosaccharide.

Surface Plasmon Resonance Analysis of Interaction of KAAs with HIV Envelope Protein gp120 {#Sec15}
-----------------------------------------------------------------------------------------

Interaction of KAAs, including His-rKAA-1, rKAA-1, KAA-1, and KAA-2, with the HIV envelope gp120 was analyzed by surface plasmon resonance (SPR) analysis using a BIAcore 2000 system (GE Healthcare) as described previously (Sato et al. [@CR51], [@CR53]). The recombinant glycosylated HIV-1 IIIB gp120 (baculovirus) was immobilized to give 300 resonance units on a carboxymethylated dextran-coated sensor chip (CM5, GE Healthcare). Ninety microliters of each concentration of His-rKAA-1 and rKAA-1 solution (0.98, 3.9, 7.8, and 15.6 nM) was injected into the flow cells at 30 μl/min for 3 min to observe the association and then the same amount of the running buffer HBS EP (GE Healthcare) was injected into the flow cells at 30 μl/min for 3 min to observe the dessociation. The data of rKAAs were fit globally to a simple Langmuir 1:1 binding model with local *R* ~max~ (maximum response) using BIAevaluation 3.1 software. For KAA-1 and KAA-2, lectin solutions of 0.98 nM were applied to the system and the obtained sensorgrams were compared with those of the recombinants at same concentration to evaluate the functional similarities among the natives and recombinants.

Anti-HIV Activity {#Sec16}
-----------------

The HIV-1 virus stock was prepared from the Jurkat cells transfected with an HIV-1 genome-encoding plasmid, pNL4-3, originally constructed from the NY5 and RAV proviruses (Adachi et al. [@CR1]). Infectivity of HIV-1 was measured with the median tissue culture infectious dose (TCID~50~) method using Jurkat cells. HIV-1 (100 TCID~50~) was incubated with twofold serially diluted lectins, in which their final concentrations were from 1 μM to 1 nM, at room temperature for 3 min in four or eight wells of a 96-well plate for each dilution. Jurkat cells (5 × 10^4^ cells/well) were further added and incubated for several days until cytopathic effects developed. Fifty percent endpoint of lectin concentration to neutralize virus infectivity was determined according to the Behrens-Kaerber method, and 50 % inhibitory concentration (IC~50~) was determined. Cell viability in the presence of lectins was examined by using the Cell Proliferation Kit I (MTT assay; Roche Diagnostics, Tokyo, Japan).

Results {#Sec17}
=======

Peptide Mapping of KAA-2 {#Sec18}
------------------------

Before peptide mapping, KAA-2 and ESA-2 were pyridylethylated and then purified as single peaks by RP-HPLC on YMC-Pack PROTEIN-RP column (Fig. [2a, b](#Fig2){ref-type="fig"}). The molecular masses of PE-KAA-2 and PE-ESA-2 were determined to be 28,124.0 and 28,052.0 by ESI-MS. These values were consistent with those estimated by SDS-PAGE (Fig. [2c](#Fig2){ref-type="fig"}). Peptide fragments generated by trypsin digestion of PE-KAA-2 and PE-ESA-2 were separated into a total of 26 peaks, including 18 common peaks between both, 5 specific peaks in PE-KAA-2, and 3 specific peaks in PE-ESA-2, by RP-HPLC on TSKgel ODS 120T (Fig. [3](#Fig3){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). The molecular masses of the isolated peptide fragments were determined by ESI-MS, except for a peak 22 in PE-KAA-2 and peaks 10 and 21 in PE-ESA-2. The determined masses were compared to those of the peptide fragments that are theoretically generated by trypsin digestion of PE-ESA-2 (Table [1](#Tab1){ref-type="table"}). All peptides whose masses were successfully determined were found in the PE-ESA-2 sequence, except for a peak 19, mass of which was not found in both sequences of PE-ESA-2 and trypsin used for digestion. The sequence of 167 amino acids (aa) of PE-KAA-2 was successfully predicted by comparing the sequences of 18 peptides with the same masses, which were commonly generated from both PE-KAA-2 and PE-ESA-2. Moreover, the N-terminal sequencing of the specific peptide peaks (11, 12, 15, 16, and 23) from PE-KAA-2 showed that there are at least three amino acid substitution for PE-ESA-2 (Fig. [4](#Fig4){ref-type="fig"}). The peptide sequence of a peak 10 (determined MW: 2550.8) in PE-KAA-2 could be an incompletely digested product of ^197^GKLSGANNYSVENQWGGSSAPWNK^220^ (calculated MW: 2551.7). Thus, a total of 230 aa in the whole sequence of PE-KAA-2 was successfully predicted by peptide mapping.Fig. 2Isolation of PE-KAA-2 and PE-ESA-2 by reverse-phase HPLC. PE-KAA-2 (**a**) and PE-ESA-2 (**b**) were purified by RP-HPLC on YMC-Pack PROTEIN-RP column. The eluate was monitored by absorbance at 280 nm, and the active fraction represented by a bar was recovered. Deconvoluted mass spectra of purified PE-KAA-2 (**a**) and PE-ESA-2 (**b**) using ESI-MS (LCQ) are also represented. SDS-PAGE of PE-KAA-2 (*lane 1*) and PE-ESA-2 (*lane 2*) (**c**). Five micrograms of protein was loaded in each lane. *M* molecular weight marker Fig. 3Peptide fragments generated by trypsin digestion of PE-KAA-2 and PE-ESA-2. Peptide fragments produced by trypsin digestion of PE-KAA-2 (**a**) and PE-ESA-2 (**b**) were purified by RP-HPLC on TSKgel ODS-120T column, and their enlarged images (**c**) are shown to compare the peak patterns. The peaks were numbered in serial order of retention time. Peaks 11, 12, 15, 16 and 23 and peaks 13, 20, and 21 were unique for PE-KAA-2 and PE-ESA-2, respectively Table 1The molecular masses of peptide fragments produced by digesting PE-KAA-2 and PE-ESA-2 with trypsin and their corresponding sequence in ESA-2PE-KAA-2PE-ESA-2Sequence in ESA-2Peak no.Determined molecular massPeak no.Determined molecular massCalculated molecular mass11023.611023.61024.1^230^HNQNITAVK^238^21275.421275.61276.3^247^NLDGTCTYER^256^31069.931069.51070.2^180^TLEGTMQYK^188^41171.441170.81172.3^113^TLTGTMTYER^122^5746.25746.3746.9^123^EGPIGFK^129^/^257^EGPIGFK^263^6831.36831.3831.9^189^GEGPIGFR^196^71588.771588.71589.7^96^SGQGVLAVNITSSDGGK^112^82539.582540.72540.6^130^GTQSGGDTYNVENQWGGSSAPWNK^153^92540.392539.52540.6^130^GTQSGGDTYNVENQWGGSSAPWNK^153^102550.810ND112364.7--^a^121001.5----133403.53402.7^28^GNQNVMAVDVNSSDGGANLNGTMTYSGEGPIGFK^61^14957.414957.4958.1^154^AGIWALGDR^162^153490.5--163450.1 ± 3.96^b^--173348.2173348.53348.6^65^RGESNVYDVENQWGGSSAPWHAGGQFVIGSR^95^183347.3183347.53348.6^65^RGESNVYDVENQWGGSSAPWHAGGQFVIGSR^95^193375.3193375.9--203293.93293.5^199^LSGANNYSVENQWGGSSAPWNAAGDWLIGDR^229^--21ND22ND223293.03293.5^199^LSGANNYSVENQWGGSSAPWNAAGDWLIGDR^229^232759.8 ± 10.99^b^--242763.3242763.92764.0^3^YTVQNQWGGSSAPWNDAGLWILGSR^27^252763.2252763.12764.0^3^YTVQNQWGGSSAPWNDAGLWILGSR^27^262800.2262796.22764.0^3^YTVQNQWGGSSAPWNDAGLWILGSR^27^*ND* not determined^a^No consistent peak^b^Standard error of \>1.0 are represented Fig. 4The predicted amino acid sequence of native KAA-2. The results of sequence prediction by peptide mapping in KAA-2 are shown using ESA-2 sequence as a template. The peptide fragments produced by trypsin digestion of PE-KAA-2 are represented with *arrows*. The peak numbers examined by Edman degradation and their determined sequences are *underlined*. The sequences whose peptide masses were consistent with those of ESA-2 are represented in *bold*. Unidentified amino acids in KAA-2 are represented as *lower case letter* of corresponding sequence in ESA-2. *Shaded regions* in the sequence were used to design the degenerated primers for cDNA cloning

Nucleotide and Amino Acid Sequences of KAAs {#Sec19}
-------------------------------------------

cDNA cloning by RACE methods resulted in isolation of two full-length cDNAs encoding KAA isoforms (Fig. [5](#Fig5){ref-type="fig"}). Compared with the deduced amino acid sequences of the two isoforms and the partial sequence of KAA-2 predicted by peptide mapping, it was found that there are substitutions of a few amino acids to one another, furthermore indicating that KAA-2 isolated from the cultivated alga was not encoded by the two cloned cDNAs. This may be attributed to the difference of algal samples used for lectin isolation and cDNA cloning. Here, we defined the isolectin cDNA whose deduced amino acid sequence was closer to the predicted KAA-2 by peptide mapping as *KAA-2* (DDBJ/EMBL/GenBank accession No. LC007081) and the other as *KAA-1* (LC007080) (Fig. [5](#Fig5){ref-type="fig"}). KAA-1 cDNA was composed of 1027 bp containing 77 bp of 5′ untranslated region (UTR), 143 bp of 3′UTR, and 807 bp of open reading frame (ORF) which encoded 268 amino acids including an initiating methionine. KAA-2 cDNA was composed of 1161 bp containing 94 bp of 5′UTR, 257 bp of 3′UTR, and 810 bp of ORF encoding 269 amino acids including an initiating methionine (LC007081). The predicted N-terminal amino acid sequence of the mature KAAs was completely comparable in the sequence determined by Edman degradation for PE-KAA-2 (underlined sequence in Fig. [5a](#Fig5){ref-type="fig"}), indicating that KAA cDNAs do not encode signal peptide and other propeptide regions. These two KAAs showed 89.7 and 98.5 % identities to each other in nucleotide and protein levels, respectively. Amino acid sequence identities between ESA-2 and KAA-1 or KAA-2 are 98.1 and 98.9 %, respectively. KAAs also contain 4 tandem repeats of around 67 amino acids (Fig. [6](#Fig6){ref-type="fig"}) as well as ESA-2 (Hori et al. [@CR26]). These repeated sequences are highly conserved between one another and among related proteins from other organisms including bacteria (*Burkholderia oklahomensis* agglutinin (BOA, four repeats), *Myxococcus xanthus* agglutinin (MBHA, four repeats), and *Pseudomonas fluorescens* lectin (PFL, two repeats)) and cyanobacteria (*O. agardhii* (OAA, two repeats)) (Fig. [6](#Fig6){ref-type="fig"}). Similar sequence was not found in higher plants or animals by BLAST search. The sequence identities between KAA-1 and BOA, MBHA, OAA, or PFL were 58.1, 60.2, 60.6, and 62.9 %, respectively. The amino acids that interact with mannopentaose (Manα1-6(Manα1-3)Manα1-6(Manα1-3)Man), which is a branched oligomannosyl core structure of M8/9, in BOA (Koharudin et al. [@CR39]) are absolutely conserved in all repeated domains of the lectins (indicated with asterisks in Fig. [6](#Fig6){ref-type="fig"}).Fig. 5Nucleotide and deduced amino acid sequences of *KAA-1*. **a** Nucleotide and deduced amino acid sequences of the cDNA encoding KAA-1. The stop codon is shown as an *asterisk*. The *italicized* and *nonitalicized numbers* represent the positions of nucleotides and amino acids, respectively. Initiating methionine is indicated in *italic*. The 20 N-terminal amino acid sequence elucidated in Kawakubo et al. ([@CR34]) is *underlined*. **b** Comparison among deduced amino acid sequences of *KAA-1* and *KAA-2*, and the sequence predicted by peptide mapping for native KAA-2 (see Fig. [2](#Fig2){ref-type="fig"}). *Lower case letters* in native KAA-2 sequence represent the corresponding sequences in ESA-2. Amino acid substitutions among KAAs were boxed. The nucleotide sequence data of *KAA-1* and *KAA-2* appear in the DDBJ, EMBL, and GenBank databases under accession number LC007080 and LC007081, respectively Fig. 6Alignment of amino acid sequences from KAAs and related proteins. Identical and similar residues among all proteins are indicated with a black and gray background, respectively. Amino acids that interact with mannopentaose (Manα1-6(Manα1-3)Manα1-6(Manα1-3)Man) of M8/9 core unit in *Burkholderia oklahomensis* agglutinin (BOA) are indicated with *asterisks*. Data were cited from *Eucheuma serra* agglutinin-2 (ESA-2, GenBank accession No. P84331), *Burkholderia oklahomensis* agglutinin (BOA, AIO69853), *Myxococcus xanthus* agglutinin (Myxobacterial hemagglutinin (MBHA), M13831), *Oscillatoria agardhii* agglutinin (OAA, P84330), and *Pseudomonas fluorescens* lectin (PFL, ABA72252)

Preparation of Active Form of Recombinant KAA-1 {#Sec20}
-----------------------------------------------

His-rKAA-1 was successfully generated using pET system and a SHuffle T7 Express strain (Fig. [7](#Fig7){ref-type="fig"}). His-rKAA-1 was prepared in the yield of 115 mg per 1 l LB media and rKAA-1 was generated in the yield of 15 mg from 25 mg of His-rKAA-1. The molecular masses of His-rKAA-1 and rKAA-1 were calculated as 30,202.7 and 28,451.9, respectively, based on their amino acid sequences. Although the recombinants ran at about 30--35 kDa in SDS-PAGE (Fig. [7a](#Fig7){ref-type="fig"}), the molecular masses determined by ESI-MS, 30,203.7 Da for His-rKAA-1 (Fig. [7b](#Fig7){ref-type="fig"}) and 28,452.1 Da for rKAA-1 (Fig. [7c](#Fig7){ref-type="fig"}), were in good agreement with the calculated ones. Hemagglutination activities of His-rKAA-1 and rKAA-1 (each 10 μM) were 2^12^ with TRBC as well as those of native KAA-1 and KAA-2 (data not shown).Fig. 7Preparation of rKAAs. **a** Nonreducing SDS-PAGE for purified His-rKAA-1 (*lane 1*) and rKAA-1 (*lane 2*). Five micrograms of each protein was loaded. *M* molecular weight marker. ESI-MS multiply charged spectra of purified His-rKAA-1 (**b**) and rKAA-1 (**c**) were shown

Carbohydrate and Oligosaccharide Binding Specificity of rKAAs {#Sec21}
-------------------------------------------------------------

Hemagglutination-inhibition test revealed that the recombinants (His-rKAA-1 and rKAA-1) and native KAA-1 and KAA-2 preferentially bound to glycoproteins containing high-mannose type *N*-glycans such as yeast mannan and PTG and weakly to the other glycoproteins without high-mannose *N*-glycan (Table [2](#Tab2){ref-type="table"}). They had no affinity for any monosaccharide examined, including mannose. A relatively strong binding to BSM and asialo-BSM with *O*-glycans was also observed for the recombinants and native KAAs. Thus, the hemagglutination-inhibition profiles of the recombinant KAAs were consistent with those of native KAAs, regardless of the presence or absence of the His-tag peptide in its N-terminus.Table 2Hemagglutination-inhibition test of native and recombinant KAAs with sugar compoundsSugars and glycoproteinsMinimum inhibition concentrationKAA-1KAA-2His-rKAA-1rKAA-1Monosaccharides and disaccharide (mM)^a^\>100\>100\>100\>100Glycoproteins (mg/ml)  *N*-glycan type  High-mannose type   Yeast mannan31.362.531.362.5  High-mannose and complex types   Porcine thyroglobulin (PTG)15.6\<7.815.631.3   Asialo-PTG\<7.8\<7.8\<7.815.6  Complex type   Transferin\>1000\>10001000\>1000   Asialo-transferin500250250500  *N*/*O*-glycan type  Fetuin\>1000\>1000\>1000\>1000  Asialo-fetuin250250250500  *O*-glycan  Bovine submaxirally mucin (BSM)62.5125125250  Asialo-BSM31.331.362.5125^a^100 mM of monosaccharides (Glc, Man, Gal, GlcNAc, GalNAc, Rha, Fuc, Xyl, NeuAc) and a disaccharide (lactose) did not inhibit hemagglutination activities of four lectins

In oligosaccharide binding experiments by a centrifugal ultrafiltration-HPLC method with 27 PA-sugars (Figs. [8](#Fig8){ref-type="fig"} and [9](#Fig9){ref-type="fig"}), His-rKAA-1 and rKAA-1 strongly bound to five oligosaccharides (oligosaccharides 7, 8, 10, 12, and 15) belonging to high-mannose-type *N*-glycans (oligosaccharides 7--17), but hardly to complex-type *N*-glycans (oligosaccharides 1--6), oligomannoses (oligosaccharides 18--22), core structures (oligosaccharides 23 and 24), or oligosaccharides from glycolipids (oligosaccharides 25--27) (Fig. [9](#Fig9){ref-type="fig"}). Comparing the binding activities between oligosaccharides 7 (80.8 % in His-rKAA-1) and 16 (17.1 %), 8 (100 %) and 11 (19.3 %), 10 (100 %) and 13 (20.7 %), 12 (95.6 %) and 14 (36.7 %), or 15 (100 %) and 9 (12.7 %) revealed that rKAAs recognized the nonreducing terminal α1-3-linked Man of the D2 arm of branched oligomannoside, and the nonreducing terminal α1-2-linked Man in the D2 arm negatively affects for binding of rKAAs. The presence of His-tag hardly influenced to the oligosaccharide binding preferences of the recombinants although His-rKAA-1 and rKAA-1 were approximately 35 % apart in binding activities to oligosaccharides 7 and 17.Fig. 8Structures of PA-oligosaccharides used in this study. *Closed circle*, galactose; *open circle*, mannose; *closed triangle*, glucose; *open triangle*, fucose; *closed square*, *N*-acetylglucosamine; *open square*, *N*-acetylgalactosamine; *closed diamond*, *N*-acetylneuraminic acid Fig. 9Interaction analysis between rKAAs and various oligosaccharides by a centrifugal ultrafiltration-HPLC method. **a** Binding activities of rKAAs to PA-oligosaccharides. Binding activity was expressed as a ratio (%) of the amount of a bound oligosaccharide to that of an added oligosaccharide. The assay was performed in duplicate for each PA-oligosaccharide, and the activity is expressed as the average value from duplicate assays. The activities less than 10 % were cutoff for their insignificance. **b** The detailed binding activities of rKAAs with high-mannose-type *N*-glycans. *Dashed boxes* represent the nonreducing terminal α1-2-linked mannose residue in the D2 arm

Interaction of rKAAs with a Recombinant HIV Envelope Glycoprotein gp120 {#Sec22}
-----------------------------------------------------------------------

Interaction between rKAAs and HIV envelope glycoprotein gp120 was performed by SPR analysis using BIAcore2000 system. His-rKAA-1 and rKAA-1 bound to the gp120 immobilized on the chip dose-dependently (Fig. [10a, b](#Fig10){ref-type="fig"}), and binding kinetics of the interactions were well fitted to each sensorgram (overlaid red lines in Fig. [10a, b](#Fig10){ref-type="fig"}). rKAAs (Fig. [10a, b](#Fig10){ref-type="fig"}) showed high association constants (*K* ~A~) (1.48--1.61 × 10^9^ M^−1^) and low dessociation constants (*K* ~D~) in the picomolar range (6.22--6.77 × 10^−10^ M) to HIV gp120, regardless of presence of His-tag (Table [3](#Tab3){ref-type="table"}). The sensorgrams of KAAs including His-rKAA-1, rKAA-1, KAA-1, and KAA-2 at same concentration of 0.98 nM were very similar as shown in Fig. [10c](#Fig10){ref-type="fig"}. Although the resonance unit of the sensorgram in His-rKAA-1 appeared slightly higher than those of the other KAAs, it might be caused by the molecular weight difference, because the molecular weight of His-rKAA-1 having N-terminal His-tag peptide is approximately 2000 Da higher than those of the other KAAs.Fig. 10Interaction of KAAs with an HIV envelope glycoprotein gp120. SPR analyses for interaction between gp120 and His-rKAA-1 (**a**) or rKAA-1 (**b**) were analyzed with BIAcore2000. Each sensorgram represents the binding activity of rKAAs to gp120 on sensor chip. Ninety microliters of rKAA solutions of each represented concentration was injected into the flow cells at 30 μl/min for 3 min. The binding response (*black line*) in resonance units is plotted against time (seconds). Binding kinetics of the interactions between rKAAs and gp120 (*overlaid red line*) were calculated by fitting the data to Langmuir model for 1:1 binding. **c** Comparison of binding activity to gp120 among KAAs including His-rKAA-1, rKAA-1, KAA-1, and KAA-2. SPR analysis was performed using 0.98 nM of each lectin solution by the same method as described above Table 3Summary of binding kinetics of the interactions between rKAAs and gp120Lectin*k* ~a~(M^−1^ s^−1^)*k* ~d~(s^−1^)*K* ~A~(M^−1^)*K* ~D~(M)His-rKAA-18.71 × 10^5^5.90 × 10^−4^1.48 × 10^9^6.77 × 10^−10^rKAA-18.50 × 10^5^5.29 × 10^−4^1.61 × 10^9^6.22 × 10^−10^*k* ~*a*~ association rate constant, *k* ~*d*~ dissociation rate constant, *K* ~*A*~ association constant, *K* ~*D*~ dissociation constant

Anti-HIV Activities of KAAs {#Sec23}
---------------------------

In vitro anti-HIV activities of His-rKAA-1, KAA-1, and KAA-2 against HIV-1 strain (derived from pNL4-3) in Jurkat cells were determined by a neutralization assay. Serially diluted lectins and HIV-1 were reacted for 3 min at room temperature and then Jurkat cells were added and further incubated until cell fusion fully developed. Experiments were repeated at least three times for each lectin. Cell viability of Jurkat cells without HIV-1 was not affected by the same concentrations of lectins as judged by the MTT assay (data not shown). The results showed that KAAs prevented infection of HIV-1 at low nanomolar IC~50~ of 12.9, 9.2, and 7.3 nM for His-rKAA-1, KAA-1, and KAA-2, respectively (Table [4](#Tab4){ref-type="table"}).Table 4Neutralization of HIV-1 by native KAAs and a recombinant KAA-1LectinIC~50~ (nM) (±SD)KAA-19.2 ± 2.2KAA-27.3 ± 1.9His-rKAA-112.9 ± 2.2*SD* standard deviation

Discussion {#Sec24}
==========

Since Kawakubo et al. ([@CR34]) reported that the N-terminal amino acid sequences of KAAs were identical to those of ESAs, the whole primary structure of KAA-2 was considered to have a high similarity with that of ESA-2. Peptide mapping of KAA-2 using the sequence of ESA-2 as a template has elucidated 85 % (230/268 aa) of the full-length sequence. A calculated molecular mass of the predicted sequence by peptide mapping, including the corresponding sequences of ESA-2, was 28,022, which gave close agreement with that of PE-KAA-2 (28,124 including an *S*-pyridylethyl group (105 Da) (Fig. [2a](#Fig2){ref-type="fig"})). Although cDNA cloning by RACE method elucidated the full-length cDNAs encoding KAAs, both of their deduced amino acid sequences were not identical to that of the native KAA-2 predicted by peptide mapping (Fig. [5b](#Fig5){ref-type="fig"}). The calculated molecular mass from their sequences were 27,881.24 and 28,007.41, respectively, and were also inconsistent with that of native KAA-2. We defined one of the two KAA cDNAs as *KAA-2,* whose amino acid sequence was more similar to native KAA-2 and ESA-2 and the other as *KAA-1*. The slight sequence differences between native KAA-2 and deduced KAA-2 might be individual variability in algal samples used. cDNA cloning has also elucidated that the transcripts of *KAA*s do not contain the region encoding a signal peptide sequence (Fig. [5](#Fig5){ref-type="fig"}), which targets the proteins from the cytosol to the cytoplasmic membrane (prokaryotes) or to the endoplasmic reticulum membrane (eukaryotes) (Imai and Nakai [@CR31]), as well as that of *OAA* from a cyanobacterium (Sato and Hori [@CR49]). It has been reported that cDNAs encoding a lectin from *Euonymus europaeus* (EEA) and EUL protein from *Arabidopsis thaliana* (ArathEULS3) do not encode a signal peptide and these translated product located in the nucleus and cytoplasm (Van Hove et al. [@CR58]) as well as a GNA ortholog from rice that lacks the signal peptide and propeptide sequence (Fouquaert et al. [@CR19]). In addition, there are not any known cellular localization signals in the primary structure of KAAs (data not shown). It suggests that KAAs are also synthesized on free ribosomes and located in nucleocytoplasm. There is only a report as to the cellular localization of KAA orthologs; Nelson et al. ([@CR43]) reported that MBHA, a KAA ortholog from a myxobacterium, localizes at the specific sites on the surface of developmental cells but not vegetated cells and suggested their function in cellular interactions during aggregation. Detailed cellular localization of KAA should be elucidated and will help to predict their functions in the algal bodies.

KAAs contain four tandem repeat domains in a molecule (Fig. [6](#Fig6){ref-type="fig"}). All the lectins of this family from algae are supposed to be composed of four tandem repeat domains commonly, contrary to those from cyanobacteria and bacteria; in cyanobacteria, OAA composes of two repeats (Sato et al. [@CR51]; Sato and Hori [@CR49]) and a hypothetical protein from *Lyngbya* sp. (Accession No. ZP_016222182) does four repeats (Sato and Hori [@CR49]); in bacteria, PFL composes of two repeats (Sato et al. [@CR54]) and BOA (Whitley et al. [@CR61]) and MBHA (Koharudin et al. [@CR39]) do four repeats (Fig. [6](#Fig6){ref-type="fig"}). Interestingly, several amino acid residues (23 aa per a single repeat domain) are absolutely conserved in all the domains among 7 lectins shown in Fig. [6](#Fig6){ref-type="fig"}. The amino acid residues (7 aa per a single repeat domain) which interact with mannopentaose of a branched oligomannosyl core of M8/9 in BOA (Whitley et al. [@CR61]) are also conserved (Fig. [6](#Fig6){ref-type="fig"}). This structural kinship suggested that lectins belonging to this lectin family might have similar carbohydrate-binding specificities.

A detailed oligosaccharide binding analysis by the centrifugal ultrafiltration-HPLC method using PA-sugars revealed that the recombinants, His-rKAA-1 and rKAA-1, preferentially recognized exposed α1-3Man in the D2 arm of high-mannose *N*-glycans (Figs. [8](#Fig8){ref-type="fig"} and [9](#Fig9){ref-type="fig"}) as previously reported for native KAA-2 (Sato et al. [@CR52]). The nonreducing terminal α1-2-linked Man in the D2 arm tended to more negatively affect for binding to rKAAs than native KAA-2. The recognition mode of KAAs is absolutely different from the other high-mannose specific antiviral lectins including CV-N, GRFT, SVN, MVL, and AH (Koharudin and Gronenborn [@CR37]). We also reported the same oligosaccharide binding properties in ESA-2 (Hori et al. [@CR26]) and OAA (Sato et al. [@CR51]) and recently in KSA from *K. striatum* (Hung et al. [@CR28]) and EDA from *E. denticulatum* (Hung et al. [@CR29]). A lectin PFL from *Pseudomonas fluorescens* Pf0-1 belonging to this lectin family also tends to preferentially recognize high-mannose glycans with α1-3 Man exposed in the D2 arm but not to other sugar types including complex *N*-glycans and *O*-glycans, as revealed by screening with a glycan array having 611 glycan targets (Sato et al. [@CR54]). Three-dimensional structural analyses for glycan-bound OAA (Koharudin et al. [@CR38]; Koharudin and Gronenborn [@CR36]), PFA (identical to PFL), MBHA (Koharudin et al. [@CR39]), and BOA (Whitley et al. [@CR61]) supported their strict binding specificities; the amino acid residues which were revealed to interact with branched mannoside in the high-mannose glycans by tertiary structural analyses were absolutely conserved in all the lectins of this family as mentioned above (Fig. [6](#Fig6){ref-type="fig"}). In previous (Sato et al. [@CR52]) and present studies, native KAA-2 and rKAAs bound to high-mannose-type oligosaccharides but not or little to oligomannoses including PA-mannopentaose (Manα1-6(Manα1-3)Manα1-6(Manα1-3)Man-PA) (oligosaccharide 22 in Fig. [8](#Fig8){ref-type="fig"}), suggesting a possibility that the reducing terminal disaccharide GlcNAc-GlcNAc is necessary for KAAs to bind to high-mannose *N*-glycans. On the other hand, Koharudin and Gronenborn ([@CR36]) showed that OAA binds to this type of mannopentaose (not pyridylaminated), by NMR binding studies, and suggested that the reducing terminal disaccharide was not essential for OAA to bind to those glycans. Exactly, PA-oligosaccharides used in this study possessed the reducing terminal residues with ring-opening structures by pyridylamination, including free oligomannoses (PA-oligosaccharides 18--22 in Fig. [8](#Fig8){ref-type="fig"}). Thus, it might be attributable to such ring-opening of the reducing terminal residues that KAAs did not bind to the PA-oligomannoses, including mannopentaose (Manα1-6(Manα1-3)Manα1-6(Manα1-3)Man-PA) (oligosaccharide 22 in Figs. [8](#Fig8){ref-type="fig"} and [9](#Fig9){ref-type="fig"}). Although we have not elucidated the structure of a KAA-mannopentaose complex, it is strongly predicted that KAA, as well as OAA (Koharudin et al. [@CR38]), requires the reducing terminal mannose having the ring structure for binding to mannopentaose, unlike CV-N and GRFT that do not directly interact with the reducing terminal mannose (Ziolkowska et al. [@CR67]; Ziolkowska and Wlodawer [@CR66]).

SPR analyses revealed that rKAAs bound to HIV envelope glycoprotein gp120 with high association constants (1.48--1.61 × 10^9^ M^−1^) as well as native KAAs did (Fig. [10](#Fig10){ref-type="fig"}). gp120 is extensively glycosylated with N-linked complex and high-mannose carbohydrates accounting for about half of its molecular weight (Geyer et al. [@CR20]), suggesting that KAAs can bind gp120 with a high affinity for the high-mannose sugars. Supposed from their strong binding to the gp120, KAAs represented potent anti-HIV activities at IC~50~ of nanomolar levels (7.3--12.9 nM, Table [4](#Tab4){ref-type="table"}) in virus neutralization assay with Jurkat cells. The activities were comparable to those of OAA (12 nM of IC~50~ against HIV-1 (R9) in TZM-b1 cells (Koharudin et al. [@CR39]); 45 nM of EC~50~ against HIV-1 X4 in MT-4 cells (Sato et al. [@CR51])), MBHA (15 nM of IC~50~ against HIV-1 (R9) in TZM-b1 cells (Koharudin et al. [@CR39])), BOA (12.2 nM of IC~50~ against HIV-1 (R9) in TZM-b1 cells (Whitley et al. [@CR61])), and ESA-2 (165 nM of EC~50~ against HIV-1 X4 in MT-4 cells (Sato et al. [@CR51])). There are a lot of HIV-1 strains, being suggested that there may be distinct sugar structures on their envelope gp120 (Zhang et al. [@CR65]). The difference of anti-HIV activities, such as the activities of OAA against HIV-1 (R9) in TZM-b1 and HIV-1 X4 in MT-4 cells, may be caused by the difference of virus strains and cells (Huskens and Schols [@CR30]) used in the experiments. The anti-HIV activities of CV-N and GRFT were reported as 0.4 nM (against HIV-1 (R9) in TZM-b1 cells) and 0.04 nM (against HIV-1 X4 in MT-4 cells) of IC~50~ (or EC~50~), respectively (Koharudin et al. [@CR39]; Mori et al. [@CR42]). The interaction between GRFT and HIV-1 gp120 IIIB (X4) was also elucidated by Xue et al. ([@CR63]) via a SPR analysis using a BIAcore T200; the dissociation constant of GRFT with the gp120 is 6.93 × 10^−11^ M, which is tenfold lower than those of KAAs (6.22--6.77 × 10^−10^ M) (Fig. [10](#Fig10){ref-type="fig"}). These relatively strong anti-HIV-1 activities of CV-N and GRFT and the robust interaction of GRFT with gp120 come from the multivalency of binding sites on the lectins and that of epitopes on the high-mannose oligosaccharides (Koharudin and Gronenborn [@CR37]). Although the antiviral activities of KAAs are lower than those of CV-N and GRFT, the oligomannose epitopes recognized by KAAs are different from those recognized by CV-N and GRFT. Since high mutation rate in HIV-1 can rapidly produce the resistant viruses against these antiviral lectins (Witvrouw et al. [@CR62]; Huang et al. [@CR27]), multilateral and synergistic use of the antiviral lectins whose recognition epitopes in oligosaccharides are different from one another can be effective as Férir et al. ([@CR18]) represented.

We searched higher plant lectins similar to KAAs by in silico screening for genome sequences of soybean *Glycine max*, rice *Oryza sativa*, and *Arabidopsis*; however, higher plant genomes encode no lectins similar to this lectin family (data not shown) as Jiang et al. ([@CR32]) reported a genome-wide screening of higher plant lectins. This lectin family is found to date only in lower organisms including eukaryotes of red algae and prokaryotes of cyanobacteria and bacteria. The biofunctional mechanism(s) where this lectin family preferentially binds to high-mannose carbohydrates having an exposed α1-3 Man in the D2 arm of branched oligomannoside is still uncovered. As Yoshiie et al. ([@CR64]) reported that the *N*-glycans of glycoproteins in red algae are predominantly high-mannose types, the internal ligands of KAAs could exist in the cells, implied from the predicted nucleocytoplasmic localization of the lectins as described before. However, the lectins peculiar to these lower organisms may have common function(s), such as host defense against infections of invasive viruses, bacteria, or fungi to these organisms as well as several cytoplasmic/nuclear plant lectins, including amaranthins, *Euonymus* lectin-like (EUL)-related lectins, jacalin-related lectins, and nictaba-related lectins, have an important role in plant defense against pathogens (Lannoo and Van Damme [@CR40], [@CR41]; Dias Rde et al. [@CR16]; De Schutter and Van Damme [@CR14]).

This study showed that the lectins from the cultivated alga *K. alvarezii* inhibit the HIV virus entry to the host cells through binding to the virus envelope glycoprotein gp120 and confirmed their activities using its recombinants. These results suggested that KAAs have potentiality to represent broad antiviral activities against viruses possessing high-mannose glycans on their envelope such as HCV, HHV, SARS-CoV, and Ebola virus, as well as native KAA-2 did against influenza viruses (Sato et al. [@CR52]). It is important that antiviral lectins are isolated from a globally cultivated edible algal species in contrast that any other homologous anti-HIV lectins are derived from bacteria (BOA, PFL, MBHA), a cyanobacterium (OAA), and an uncultivated alga (ESA-2); KAAs can be purified in a relatively high yield of 270 mg per 100 g of freeze-dried alga (Kawakubo et al. [@CR34]). These functional lectins will become a strong tool by being supplied in bulk as both native and recombinant forms, which are almost identical in their carbohydrate specificities and antiviral activities.
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